ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research
Aberrant activation of RET is a critical driver of growth and proliferation in diverse solid tumours. Multikinase inhibitors (MKIs) showing anti-RET activities have been tested in RET-altered tumours with variable results. The low target specificity with consequent increase in side-effects and off-t...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
14 January 2021
|
| In: |
Annals of oncology
Year: 2021, Jahrgang: 32, Heft: 3, Pages: 337-350 |
| ISSN: | 1569-8041 |
| DOI: | 10.1016/j.annonc.2020.11.021 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.annonc.2020.11.021 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0923753420431977 
|
| Verfasserangaben: | C. Belli, F. Penault-Llorca, M. Ladanyi, N. Normanno, J.-Y. Scoazec, L. Lacroix, J.S. Reis-Filho, V. Subbiah, J.F. Gainor, V. Endris, M. Repetto, A. Drilon, A. Scarpa, F. André, J.-Y. Douillard & G. Curigliano |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1756677980 | ||
| 003 | DE-627 | ||
| 005 | 20230426092553.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210430s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2020.11.021 |2 doi | |
| 035 | |a (DE-627)1756677980 | ||
| 035 | |a (DE-599)KXP1756677980 | ||
| 035 | |a (OCoLC)1341407624 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Belli, Carmen |e VerfasserIn |0 (DE-588)1235836215 |0 (DE-627)1760995711 |4 aut | |
| 245 | 1 | 0 | |a ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research |c C. Belli, F. Penault-Llorca, M. Ladanyi, N. Normanno, J.-Y. Scoazec, L. Lacroix, J.S. Reis-Filho, V. Subbiah, J.F. Gainor, V. Endris, M. Repetto, A. Drilon, A. Scarpa, F. André, J.-Y. Douillard & G. Curigliano |
| 264 | 1 | |c 14 January 2021 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 30.04.2021 | ||
| 520 | |a Aberrant activation of RET is a critical driver of growth and proliferation in diverse solid tumours. Multikinase inhibitors (MKIs) showing anti-RET activities have been tested in RET-altered tumours with variable results. The low target specificity with consequent increase in side-effects and off-target toxicities resulting in dose reduction and drug discontinuation are some of the major issues with MKIs. To overcome these issues, new selective RET inhibitors such as pralsetinib (BLU-667) and selpercatinib (LOXO-292) have been developed in clinical trials, with selpercatinib recently approved by the Food and Drug Administration (FDA). The results of these trials showed marked and durable antitumour activity and manageable toxicity profiles in patients with RET-altered tumours. The European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to review the available methods for the detection of RET gene alterations, their potential applications and strategies for the implementation of a rational approach for the detection of RET fusion genes and mutations in human malignancies. We present here recommendations for the routine clinical detection of targetable RET rearrangements and mutations. | ||
| 650 | 4 | |a fluorescence hybridization | |
| 650 | 4 | |a next-generation sequencing | |
| 650 | 4 | |a RET | |
| 700 | 1 | |a Penault-Llorca, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ladanyi, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Normanno, N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Scoazec, J. -Y. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lacroix, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reis-Filho, J. S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Subbiah, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gainor, J. F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Endris, Volker |e VerfasserIn |0 (DE-588)1063753686 |0 (DE-627)812590961 |0 (DE-576)422898198 |4 aut | |
| 700 | 1 | |a Repetto, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Drilon, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Scarpa, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a André, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Douillard, J. -Y. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Curigliano, G. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 32(2021), 3 vom: März, Seite 337-350 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research |
| 773 | 1 | 8 | |g volume:32 |g year:2021 |g number:3 |g month:03 |g pages:337-350 |g extent:14 |a ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.annonc.2020.11.021 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0923753420431977 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210430 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 1063753686 |a Endris, Volker |m 1063753686:Endris, Volker |d 910000 |d 912000 |e 910000PE1063753686 |e 912000PE1063753686 |k 0/910000/ |k 1/910000/912000/ |p 10 | ||
| 999 | |a KXP-PPN1756677980 |e 3920395018 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"14 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2003498-2"],"eki":["320428796"],"issn":["1569-8041"]},"origin":[{"dateIssuedDisp":"1990-","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedKey":"1990","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford"}],"part":{"extent":"14","volume":"32","text":"32(2021), 3 vom: März, Seite 337-350","pages":"337-350","issue":"3","year":"2021"},"pubHistory":["1.1990 -"],"language":["eng"],"corporate":[{"display":"European Society for Medical Oncology","roleDisplay":"Herausgebendes Organ","role":"isb"}],"recId":"320428796","disp":"ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical researchAnnals of oncology","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"title":[{"title_sort":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology","title":"Annals of oncology"}]}],"origin":[{"dateIssuedDisp":"14 January 2021","dateIssuedKey":"2021"}],"id":{"eki":["1756677980"],"doi":["10.1016/j.annonc.2020.11.021"]},"name":{"displayForm":["C. Belli, F. Penault-Llorca, M. Ladanyi, N. Normanno, J.-Y. Scoazec, L. Lacroix, J.S. Reis-Filho, V. Subbiah, J.F. Gainor, V. Endris, M. Repetto, A. Drilon, A. Scarpa, F. André, J.-Y. Douillard & G. Curigliano"]},"note":["Gesehen am 30.04.2021"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1756677980","language":["eng"],"title":[{"title":"ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research","title_sort":"ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research"}],"person":[{"family":"Belli","given":"Carmen","roleDisplay":"VerfasserIn","display":"Belli, Carmen","role":"aut"},{"given":"F.","family":"Penault-Llorca","role":"aut","display":"Penault-Llorca, F.","roleDisplay":"VerfasserIn"},{"family":"Ladanyi","given":"M.","roleDisplay":"VerfasserIn","display":"Ladanyi, M.","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Normanno, N.","role":"aut","family":"Normanno","given":"N."},{"roleDisplay":"VerfasserIn","display":"Scoazec, J. -Y.","role":"aut","family":"Scoazec","given":"J. -Y."},{"role":"aut","display":"Lacroix, L.","roleDisplay":"VerfasserIn","given":"L.","family":"Lacroix"},{"role":"aut","display":"Reis-Filho, J. S.","roleDisplay":"VerfasserIn","given":"J. S.","family":"Reis-Filho"},{"family":"Subbiah","given":"V.","display":"Subbiah, V.","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Gainor, J. F.","role":"aut","family":"Gainor","given":"J. F."},{"display":"Endris, Volker","roleDisplay":"VerfasserIn","role":"aut","family":"Endris","given":"Volker"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Repetto, M.","given":"M.","family":"Repetto"},{"family":"Drilon","given":"A.","roleDisplay":"VerfasserIn","display":"Drilon, A.","role":"aut"},{"given":"A.","family":"Scarpa","role":"aut","display":"Scarpa, A.","roleDisplay":"VerfasserIn"},{"given":"F.","family":"André","role":"aut","roleDisplay":"VerfasserIn","display":"André, F."},{"family":"Douillard","given":"J. -Y.","roleDisplay":"VerfasserIn","display":"Douillard, J. -Y.","role":"aut"},{"given":"G.","family":"Curigliano","role":"aut","roleDisplay":"VerfasserIn","display":"Curigliano, G."}]} | ||
| SRT | |a BELLICARMEESMORECOMM1420 | ||